Systemax Inc. (SYX) Reaches $17.89 52-Week High; Tetraphase Pharmaceuticals (TTPH) Shorts Up By 1.12%

June 14, 2017 - By Vivian Currie

Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) had an increase of 1.12% in short interest. TTPH’s SI was 1.44M shares in June as released by FINRA. Its up 1.12% from 1.43 million shares previously. With 482,400 avg volume, 3 days are for Tetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH)’s short sellers to cover TTPH’s short positions. The SI to Tetraphase Pharmaceuticals Incorporated’s float is 3.92%. About 20,919 shares traded. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has risen 106.58% since June 14, 2016 and is uptrending. It has outperformed by 89.88% the S&P500.

The stock of Systemax Inc. (NYSE:SYX) hit a new 52-week high and has $18.61 target or 4.00% above today’s $17.89 share price. The 7 months bullish chart indicates low risk for the $692.44 million company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $18.61 price target is reached, the company will be worth $27.70 million more. About 15,175 shares traded. Systemax Inc. (NYSE:SYX) has risen 77.10% since June 14, 2016 and is uptrending. It has outperformed by 60.40% the S&P500.

Since March 15, 2017, it had 1 insider buy, and 0 insider sales for $82,370 activity. The insider GAGE L PATRICK bought $82,370.

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $279.78 million. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. It currently has negative earnings. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Among 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Tetraphase Pharmaceuticals had 16 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) earned “Buy” rating by Stifel Nicolaus on Thursday, August 6. The rating was maintained by Brean Capital with “Buy” on Thursday, August 6. The firm has “Neutral” rating given on Wednesday, September 9 by Wedbush. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has “Outperform” rating given on Friday, March 10 by BMO Capital Markets. Brean Capital downgraded Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) on Wednesday, September 9 to “Hold” rating. On Wednesday, September 9 the stock rating was downgraded by Nomura to “Neutral”. The firm has “Neutral” rating by Gabelli given on Friday, May 13. The company was upgraded on Thursday, November 19 by SunTrust. On Wednesday, September 9 the stock rating was downgraded by Needham to “Hold”. The firm has “Neutral” rating by Robert W. Baird given on Wednesday, September 9.

Investors sentiment increased to 1.29 in Q4 2016. Its up 0.17, from 1.12 in 2016Q3. It increased, as 12 investors sold Tetraphase Pharmaceuticals Inc shares while 22 reduced holdings. 12 funds opened positions while 32 raised stakes. 17.45 million shares or 11.89% less from 19.80 million shares in 2016Q3 were reported. Blackrock Institutional Tru Na has 899,092 shares. Canada Pension Plan Invest Board owns 0.02% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 1.65M shares. Tudor Inv Corp Et Al holds 18,425 shares. First Quadrant Ltd Partnership Ca accumulated 36,670 shares or 0% of the stock. Art Advsrs Limited Liability invested in 25,900 shares. Joel Isaacson Ltd Llc has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Sunbelt Secs holds 0% or 6,000 shares. Credit Suisse Ag accumulated 0% or 23,327 shares. Tekla Cap Mngmt Lc invested 0.03% in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Federated Pa invested in 130,809 shares or 0% of the stock. National Bank & Trust Of Ny Mellon, New York-based fund reported 181,783 shares. Invesco has 34,690 shares. Tiaa Cref Investment Mgmt Ltd Com has 127,172 shares. Loring Wolcott And Coolidge Fiduciary Advisors Ltd Liability Partnership Ma holds 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 3,600 shares. Parallax Volatility Advisers L P stated it has 2,600 shares.

Investors sentiment decreased to 1.22 in Q4 2016. Its down 0.33, from 1.55 in 2016Q3. It turned negative, as 2 investors sold Systemax Inc. shares while 21 reduced holdings. 7 funds opened positions while 21 raised stakes. 9.18 million shares or 1.96% less from 9.36 million shares in 2016Q3 were reported. Deutsche Commercial Bank Ag reported 13,257 shares. Ingalls Snyder Limited Liability Company accumulated 108,319 shares. Panagora Asset, a Massachusetts-based fund reported 42,846 shares. 11,145 were accumulated by Nationwide Fund Advisors. Blackrock Institutional Na holds 252,833 shares or 0% of its portfolio. 2,900 are owned by Bessemer Group Incorporated Inc. State Bank Of Montreal Can holds 87 shares or 0% of its portfolio. 14,703 were accumulated by Martingale Asset Management L P. Int accumulated 6,611 shares. Smith Thomas W reported 76,500 shares or 0.73% of all its holdings. 141,414 were reported by Bancshares Of New York Mellon Corp. Pnc Fin Serv Gru Inc invested in 0% or 1,372 shares. The New York-based Weber Alan W has invested 1.27% in Systemax Inc. (NYSE:SYX). Manufacturers Life Insur The reported 1,057 shares. Tfs Capital Limited Liability Com reported 12,480 shares.

Systemax Inc. is a direct marketer of brand name and private label products. The company has market cap of $692.44 million. The Company’s divisions are Industrial Products Group , EMEA Technology Products Group (EMEA), and Corporate and Other (Corporate). It has a 190.14 P/E ratio. The IPG segment sells an array of maintenance, repair and operational (MRO) products, which are marketed in North America.